9 Things Optometrists Know About Dry Eye That Most Patients Never Get Told

FACT 1 OF 9

86% of dry eye is caused by gland dysfunction — not insufficient tears

Most patients are told they have dry eyes as if the problem is simply a lack of moisture. The clinical reality is more specific. A landmark analysis published in Cornea (Lemp et al., 2012) examining 299 dry eye patients found that 86% had meibomian gland dysfunction — MGD — as either the primary or contributing cause of their condition.

Meibomian glands are a row of tiny oil-producing glands that line the upper and lower eyelids. Their job is to secrete a thin lipid layer that sits on top of the tear film and prevents it from evaporating. When these glands are blocked or damaged, the lipid layer breaks down — and tears evaporate faster than the eye can replenish them.

This means the vast majority of dry eye sufferers are not suffering from a deficit of tears. They are suffering from accelerated tear evaporation caused by a blocked delivery system. These are meaningfully different conditions that respond to meaningfully different treatments.

Lemp MA et al., Cornea, 2012.

FACT 2 OF 9

The tiny oil glands in your eyelids can become permanently blocked

Meibomian glands produce meibum — a complex lipid mixture with a consistency similar to olive oil when healthy. When gland function is disrupted by screen time, hormonal changes, aging, contact lens use, or inflammation, this oil gradually thickens. Over time it solidifies to something closer to butter or toothpaste. Once solidified, it can no longer flow freely through the gland opening onto the tear film.

The glands themselves do not fail all at once. Blockage is progressive. In the early stages, glands are congested but still functional — they can be unblocked with sustained heat treatment. In later stages, the gland tissue itself begins to atrophy. The important clinical distinction: congested glands can be treated. Atrophied glands cannot be reversed.

FACT 3 OF 9

Eye drops treat a symptom — they cannot address the cause

Lubricating eye drops add moisture to the ocular surface. For the small proportion of dry eye patients with genuinely insufficient tear production, this directly addresses the cause of their symptoms.

For the 86% with MGD as the primary driver, drops work differently. They temporarily supplement the evaporating tear film. Symptoms ease for 20 to 40 minutes. Then evaporation accelerates again, because the lipid layer is still compromised, and the blocked glands still are not delivering oil. The cycle repeats.

This is not a failure of the drops themselves. They were designed for aqueous-deficient dry eye. They do what they were designed to do. The problem is that they are being prescribed for a condition they were never designed to treat.

FACT 4 OF 9

Gland atrophy is irreversible — and most patients do not know it is happening

This is the piece of information that the standard dry eye consultation most often omits — not out of negligence, but because it takes time to explain and the clinical implications are uncomfortable.

Once meibomian gland tissue atrophies, it does not regenerate. Imaging technology — meibography — can now visualise gland loss in real time. Studies using meibography consistently show that gland dropout correlates directly with disease duration and symptom severity. Patients who have been on ineffective treatment protocols for years are almost always found, on imaging, to have significantly greater gland loss than those who received effective early intervention.

The implication is straightforward: every month spent on an inadequate treatment protocol is a month during which progressive, irreversible gland loss may be occurring undetected.

FACT 5 OF 9

The gold-standard clinical treatment costs over $700 per session — and is not covered by insurance

The most effective in-office treatment for MGD is thermal pulsation therapy — procedures like LipiFlow. It delivers precisely controlled heat and pressure directly to the inner eyelids, softening and expressing blocked meibum. Clinical trials show measurable improvement in gland function and tear film stability.

A single session costs approximately $700 to $1,000. It is not covered by insurance. Results typically last six to twelve months, after which the procedure needs to be repeated. For patients who need sustained maintenance, the annual cost runs to $1,400 or more.

The vast majority of MGD patients — including those with moderate to severe disease — never access this treatment because the economics make it unsustainable.

FACT 6 OF 9

Warm compresses were the right idea — but they have a physics problem

The principle behind warm compress therapy is clinically sound. Blocked meibum needs to be heated above its melting point before it can be expressed from the gland. Research has confirmed that the threshold temperature for liquefying solidified meibomian oil is approximately 40°C — and that this temperature needs to be sustained for a minimum of 10 minutes to have a meaningful therapeutic effect.

The problem is that standard warm compresses — whether a heated flannel, a microwaveable mask, or a gel pad — lose therapeutic heat within 2 to 3 minutes of application. By the time 4 minutes have passed, most compress devices have dropped below the 40°C threshold. The remaining 6 minutes of the recommended session deliver no therapeutic heat at all.

Patients are not failing warm compress therapy. Warm compress therapy is physically unable to do what it needs to do.

Borchman D., Current Eye Research, 2019.

FACT 7 OF 9

Steam delivers what compresses cannot — sustained therapeutic temperature with simultaneous moisture

Steam heat transfers to tissue more efficiently than dry heat. It maintains temperature consistency throughout a session without cooling. And it delivers therapeutic moisture directly to the ocular surface and eyelid tissue simultaneously — hydrating the surface while the heat works on the glands.

A 2025 systematic review and meta-analysis published in Contact Lens and Anterior Eye (Ballesteros-Sánchez et al.) examined 7 randomised controlled trials involving 367 patients. When comparing steam-based moisture chamber devices directly against standard warm compress devices, tear film breakup time — the primary clinical marker of tear film stability — was significantly better in the steam group (p = 0.005).

This is the highest level of clinical evidence: a meta-analysis of randomised trials showing steam-based devices outperforming the standard-of-care warm compress on the measure that matters most.

Ballesteros-Sánchez et al., Contact Lens and Anterior Eye, 2025.

FACT 8 OF 9

Clinical-grade steam therapy is now available for home use — for less than one clinic session

The Beminda Steam Therapy Pro delivers continuous moist heat at 42°C for a full 10-minute session. It is worn hands-free over both eyes simultaneously, requires no microwave and no reheating. The device reservoir accepts the Beminda Eye Hydration Complex — a saline formulation with trehalose, taurine, B6, and B12 — so the steam itself is nutrient-infused rather than plain water vapour.

The Precision Eyelid Massager completes the daily protocol by helping express softened oils after the steam session — closing the loop that warm compresses leave open.

The complete three-component system addresses MGD from multiple angles within a single daily routine: sustained moist heat to melt the blockage, the hydration complex to support tear film quality, and eyelid massage to help clear expressed oils. It retails at $129.97 — less than 20% of the cost of a single LipiFlow session.

FACT 9 OF 9

Patients who address MGD consistently and early preserve function that cannot be restored later

The clinical argument for early and consistent MGD treatment is not primarily about comfort — it is about preservation. Glands that are functioning today, treated consistently, will fare meaningfully better than glands left on inadequate protocols for years.

Research on gland atrophy shows a dose-response relationship between disease duration and gland loss. The longer the condition persists without effective treatment, the greater the structural damage. Conversely, patients who establish a consistent daily steam therapy routine at earlier stages retain better gland function over time.

MGD is unusual as a condition: the stakes of inaction are architectural, not just symptomatic. Treating it is not only about feeling better today. It is about preserving the glandular tissue that produces the oil your tear film will always require.